“If you have knowledge, let others light their candles in it.”
— Margaret Fuller

POSTER ABSTRACT SUBMISSIONS



STUDENTS/RESIDENTS/FELLOWS POSTER SESSION

Some posters will be selected for a presentation by one of the authors during the Poster Session; more information to follow. The five best posters will then be determined, which will include the following categories based on the status of the first author: student, resident, and fellow.

ABSTRACT

Abstract submissions for EnVision 2025 are now open! Click here to submit. If your abstract is chosen to be presented, you will be contacted via email. The deadline to submit a abstract submission is November 30, 2024.

The abstract must be saved as a PDF file containing the following elements:

  • Title;

  • Presenter;

  • E-mail of presenter;

  • Co-authors;

  • Affiliations of presenter and co-authors;

  • Financial disclosures (see DISCLOSURES below);

  • Four sections: Purpose, Methods, Results, Conclusions (maximum number of words = 300).


POSTER

If your abstract is selected for the Poster Session, your poster must be submitted as a PowerPoint file, 16:9 format, with a minimum of 5 slides and a maximum of 8. Final posters as well as certificates of student status, residency, or fellowship must be submitted by January 2025.


MEETING REGISTRATION

All presenters must register and pay the fees to attend the meeting and the poster session. Registration fees will be waived for students, residents, and fellows. A letter from the university, residency, or fellowship program confirming the status of the student/resident/fellow must be obtained and incorporated into the abstract file.

 

All presenters are expected to:

  • Present the same work described in the abstract, with the same title, authors, and content.

  • Fully disclose all commercial relationships relevant to the subject matter for themselves and all co-authors of the abstract for the prior 12 months (see DISCLOSURES below).

  • Design a poster that is independent, objective, scientifically rigorous, balanced, and free of bias.

  • Assure that scientific studies utilized or referenced in their poster are from sources acceptable to the scientific and medical community.

  • The U.S. Food and Drug Administration (FDA) requires disclosures be made to session participants of unlabeled or unapproved uses of drugs or devices contained in poster/presentations. You must disclose any such uses when you are discussing unlabeled or unapproved uses of drugs or devices.

 

DISCLOSURES

Full disclosure must be listed in the abstract and on the poster. First/presenting authors must fully disclose to session participants all commercial relationships relevant to the subject matter for themselves and all co-authors of the abstract for the prior 12 months. Full disclosure will include the name(s) of the commercial interest and the nature of the relationship (Consultant/Advisor; Employee; Lecture Fees; Equity Owner; Patents/Royalty; Grant Support). Indicate “None” if no relationships exist.

 

CONTACT INFORMATION

For general questions about the poster and poster session, please contact by email: info@envisionsummit.org